REGLAN (metoclopramide hydrochloride) by ANI Pharmaceuticals is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 1980.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
REGLAN (metoclopramide HCl) is an oral small-molecule dopamine antagonist that enhances upper GI motility and prevents nausea/vomiting. It works by sensitizing GI tissues to acetylcholine and blocking dopamine receptors in the chemoreceptor trigger zone. It is indicated for gastroesophageal reflux, diabetic gastroparesis, and chemotherapy-induced nausea.
Product is in LOE-approaching stage with modest Part D utilization; brand team likely focused on cost management and generic transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on REGLAN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moREGLAN careers are concentrated in generic transition, compliance, and cost management rather than innovative product development. This product offers limited upside but provides stable, specialized experience in mature brand stewardship and post-LOE commercial strategy.